Hall Laurie J Trustee Has $105,000 Stake in Hologic, Inc. (NASDAQ:HOLX)

Hall Laurie J Trustee lowered its holdings in Hologic, Inc. (NASDAQ:HOLX) by 10.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,449 shares of the medical equipment provider’s stock after selling 176 shares during the quarter. Hall Laurie J Trustee’s holdings in Hologic were worth $105,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. State Street Corp increased its stake in shares of Hologic by 0.8% in the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after buying an additional 81,057 shares during the period. FMR LLC increased its position in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the period. The Manufacturers Life Insurance Company lifted its position in Hologic by 0.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock valued at $208,051,000 after purchasing an additional 18,774 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Hologic by 8.6% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after purchasing an additional 195,285 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after buying an additional 544,889 shares during the period. 94.73% of the stock is owned by institutional investors.

Insider Activity at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.75% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on HOLX. Evercore ISI upped their target price on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. UBS Group upped their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Royal Bank of Canada raised their target price on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. Raymond James upped their price target on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Monday, January 13th. Seven analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Stock Down 0.3 %

NASDAQ:HOLX opened at $69.73 on Monday. The stock has a 50-day simple moving average of $74.84 and a 200 day simple moving average of $78.41. Hologic, Inc. has a 52-week low of $68.61 and a 52-week high of $84.67. The company has a market cap of $15.82 billion, a PE ratio of 20.94, a PEG ratio of 2.44 and a beta of 0.97. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same period last year, the company earned $0.89 earnings per share. The firm’s revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.